Introduction {#Sec1}
============

Epilepsy is a common but complex neurological disorder affecting approximately 0.7 % of the population (Hirtz et al. [@CR15]), but nearly one-third lack effective treatment (Engel [@CR9]; Loscher [@CR21]). Multiple genetic factors cause or contribute to the severity of epilepsy (Michelucci et al. [@CR25]), so understanding mechanisms that can modify seizure occurrence or severity could reveal novel epilepsy drug targets. While many mutations that cause human epilepsy are in ion channels, the recent description of de novo mutations in GNAO1 (Nakamura et al. [@CR27]) in early infantile epileptiform encephalopathy (EIEE17, MIM 615473) is intriguing since G protein-coupled receptors are valuable drug targets.

It has been known for some time that G-protein-coupled receptor (GPCR) signaling plays an important role in epilepsy. These receptors activate heterotrimeric G-proteins which consist of a Gα subunit and a Gβγ dimer. *Gnao1* encodes for the alpha subunit of G~o~, a G~i/o~ family member (G~i1~, G~i2~, G~i3~, G~o~) that is highly abundant in brain (Birnbaumer [@CR4]). This family of proteins inhibits adenylyl cyclase and can reduce neuronal excitability through regulation of ion channels. Blockade of the entire G~i/o~ family with pertussis toxin enhances seizure susceptibility (Ormandy and Jope [@CR28]). G~o~, in particular, plays a key role in presynaptic inhibition of neurotransmitter release through a Gβγ-mediated suppression of voltage-gated Ca^2+^ channels (Chen and Lambert [@CR5]). Also, G~o~ is activated by the A1 adenosine receptor (Fu et al. [@CR11]) which is protective in several seizure models (Chen et al. [@CR6]; Li et al. [@CR20]; Masino et al. [@CR23]). This suggests that enhancing Gα~o~ function might reduce seizure activity, consistent with our previous study showing reduced repetitive firing in a hippocampal slice model (Goldenstein et al. [@CR13]).

However, this simplified in vitro system seems not to reflect the complex nature of epilepsy in vivo. Indeed acute seizure models (Loscher [@CR21]) do not effectively assess epileptogenesis, the maladaptive changes that occur after initial excitatory stimuli which lead to further enhancement of seizure susceptibility. Epileptogenesis is thought to play a key role in the progression of human epilepsy (Morimoto et al. [@CR26]). Electrical or chemical kindling models (Bialer and White [@CR3]) attempt to assess this with repeated sub-threshold excitatory stimuli that eventually result in generalized seizures. Pentylenetetrazol (PTZ) is a non-competitive GABA~A~ antagonist. A single large dose induces seizures by engaging the brainstem (Peterson and Albertson [@CR29]), however, lower doses of PTZ, in a repeated-dose kindling protocol, preferentially activate the deep prepiriform cortex (Peterson and Albertson [@CR29]). This causes remodeling that parallels change in human epileptic brains such as mossy fiber sprouting within the dentate gyrus (Golarai et al. [@CR12]; Lee et al. [@CR19]).

Here, we describe a mouse model with features that are shared with the recently described EIEE17 syndrome of human epilepsy (Nakamura et al. [@CR27]). This heterozygous *Gnao1*^+/G184S^ mutation produces early neonatal and adult lethality accompanied by epileptiform discharges, markedly enhanced sensitivity to PTZ-induced kindling, and rare spontaneous seizures. Furthermore, we have identified a Chr17 modifier that affects both PTZ kindling and spontaneous death in our model. This animal model, as well as the modifer locus on Chr17, should provide insights into mechanisms of a human epileptiform encephalopathy as well as potential therapeutic approaches.

Materials and methods {#Sec2}
=====================

Animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals established by the National Institutes of Health, and all experimental protocols were approved by the University of Michigan Committee on the Use and Care of Animals. Detailed experimental protocols are outlined in the Supplemental Information but key information is presented here.

Generation of Gnao1 G184S mutant mice {#Sec3}
-------------------------------------

The generation of the *Gnao1* G184S knock-in mice (*tm2Rneu*) allele from a CJ7 bac library into the 129-steel derived ES line, CJ7, was previously reported (Goldenstein et al. [@CR13]) with additional details in Supplemental Information. Breeding on all genetic backgrounds was performed with *Gnao1*^+/*tm2Rneu*^ male and *Gnao1*^+/+^ females. As described in results, homozygotes were non-viable so all studies were done with heterozygous mutants. To obtain mutant mice on the B6 background, the *tm2Rneu* allele, after Neo excision, was successively backcrossed onto the C57BL/6J background (Jackson Labs stock \# 000,664). A single N6 B6-*Gnao1*^+/*tm2Rneu*^ male ancestor gave rise to all N7--N9 B6-*Gnao1*^+/*tm2Rneu*^ mice presented in this study which will be termed B6-*Gnao1*^+/G184S^. Due to reduced viability and premature lethality of the B6-*Gnao1*^+/G184S^ mutants, we were not able to generate sufficient N10+ mice for studies. F1 mice (B6-129S-F1) carrying the *Gnao1*^+/G184S^ allele were generated from crosses of *Gnao1*^+/*G184S*^ 129S1/SvImJ male mice with C57Bl/6J females. Female mice from F2 crosses (F1 brother--sister matings) were also studied for survival.

Genotyping {#Sec4}
----------

The G184S allele of *Gnao1* was identified by genomic PCR as described (Goldenstein et al. [@CR13]) with details in Supplemental Information.

Viability {#Sec5}
---------

Adult survival studies were done with group-housed B6, 129, F1, or F2 *Gnao1*^+/*G184S*^ male or female mice as indicated. Female B6 *Gnao1*^+G184S^ mutant mice also underwent video recording in their cages around the clock for up to 10 weeks using an IR camera. Cages were inspected each morning and tapes were reviewed in the event of a death within the cage.

Video EEG {#Sec6}
---------

Female mutant and control mice approximately 24 weeks old were implanted with electrodes, given one week to recover, and monitored under video EEG as described by Lee et al. ([@CR19]) with additional details in Supplemental Information. Interictal epileptiform discharges (IEDs) were assessed by manual analysis by a blinded observer since automated spike detection gave a high proportion of false positive and false negative calls. IEDs were defined as waveforms lasting 20-200 ms, at least 3 times the background activity in amplitude, disturbing the background.

Chemical kindling susceptibility {#Sec7}
--------------------------------

A PTZ kindling protocol was performed essentially as described (Wilczynski et al. [@CR31]) to assess epileptogenesis. Briefly, PTZ was administered 3 times per week at 35 mg/kg starting at 8--12 weeks of age; mice were monitored for 30 min for behavioral signs of seizures as described (Dhir [@CR8]; Grecksch et al. [@CR14]; Wilczynski et al. [@CR31]). This dose seldom elicits seizures on the first dose in wild-type mice regardless of gender or strain (lab observation). Sensitization is defined as death or two sequential sessions with a tonic--clonic seizure. The number of injections for each mouse to reach a sensitized state is reported in survival curves.

Statistical analysis {#Sec8}
--------------------

Data were analyzed using GraphPad Prism 5.0 and GraphPad QuickCalcs (GraphPad; LaJolla, CA). Proportionality of hazards for survival curves was analyzed using SAS 9.3 (SAS Institute; Cary, NC). Chi squared analysis was used to evaluate deviation from Mendelian ratios. The Gehan--Breslow--Wilcoxon test was applied to survival and kindling data since survival curves failed to meet the proportional hazard assumption required for logrank tests (Machin et al. [@CR22]). For EEG data, a parametric, an unpaired *t* test was performed with Welch's correction for unequal standard deviations. Two tailed *p* values less than 0.05 were considered significant.

Results {#Sec9}
=======

*Gnao1* G184S mutant mice die perinatally {#Sec10}
-----------------------------------------

In light of the de novo mutants of GNAO1 recently reported in early infantile epileptiform encephaolopathy (Nakamura et al. [@CR27]), we reexamined previously described mice carrying the G184S *Gnao1* mutant gain-of-function allele (*tm2Rneu*---MGI:5508226) (Goldenstein et al. [@CR13]). Heterozygous mutant mice are viable but obtained in reduced frequencies, while homozygotes are essentially not viable. From het × het crosses of *Gnao1* G184S mutants on the 129 strain background, we obtained at weaning: 20 wt, 19 het, and only 2 homozygous mutants (5 %, 1 male and 1 female). Both homozygous and heterozygous mutants were underrepresented (Fig. S1A Chi squared *χ*^2^ df(2) = 16.02 *p* \< 0.001). Similarly, after back-crossing four times onto a C57BL/6J background (N4 B6), no homozygotes survived to weaning out of fifty-five offspring from het x het crosses and hets were substantially underrepresented (21 het vs 34 wt; expected value for hets is 2 × WT or 68; Fig. S1B Chi squared *χ*^2^ df(2) = 45, *p* \< 0.0001). Sex did not influence genotype distributions on either background (data not shown).

To understand the loss of viability of mice carrying the *Gnao1* G184S allele, timed pregnancies were performed for N7 B6 het x het crosses and embryos were collected. At E18.5, genotypes did not differ from the expected Mendelian ratio (Fig. S1C), indicating that the loss of viability occurred after E18.5 but before 2 weeks of age. With close monitoring of litters, there were very few viable homozygous offspring and hets were also underrepresented (Fig. S1D, Chi squared *χ*^2^ df(2) = 8.76 *p* \< 0.02). Many homozygotes and some hets were found dead but there were no obvious anatomical abnormalities. Nissl staining performed on brains of E18.5 embryos revealed no major defects in brain structure (Fig. S2A--d). Gα~o~ protein expression in the brains of hets at 8--12 weeks of age was found to be normal, indicating that the mutation was not significantly disrupting protein levels (Fig. S2e--f).

*Heterozygous Gnao1*^+/G184S^ mice experience sudden death {#Sec11}
----------------------------------------------------------

*Gnao1* G184S B6 hets that survived to weaning (\~30 % of expected) experience lethality starting at \~80 days (11--12 weeks) with \~50 % dead by 25 weeks of age (Fig. [1](#Fig1){ref-type="fig"}a). This was due to the *Gnao1* mutant allele rather than to strain background as wild-type littermates survived to greater than 1 year (data not shown). Interestingly, there appeared to be heterogeneity in survival as the \~50 % that survived to 25 weeks showed little further premature lethality.Fig. 1*Gnao1* ^+/G184S^ mice exhibit strain-dependent lethality, seizures, and altered EEGs. **a** *Gnao1* ^+/G184S^ mutant mice on a C57BL/6J background (N7 B6) die prematurely (Gehan--Breslow--Wilcoxon df(1) = 12.8, *p* \< 0.001). **b** Early lethality is independent of gender. **c** Video monitoring revealed a seizure just prior to death (video in supplement). **d**, **e** EEG monitoring of *Gnao1* mutant and wt mice demonstrate a greater than tenfold increase in interictal epileptiform discharges (IEDs) in B6 *Gnao1* ^+/G184S^ mutant females compared to littermate wt controls (unpaired *t* test *t* = 7.37 df = 2.2, *p* \< 0.02). *Vertical bars* demark the passage of 1 s. Data represent mean ± SEM. \**p* \< 0.02

To understand the cause of death, mice were monitored three times weekly in daylight hours over 2 months. There were no evident signs of illness, weight loss, distress, or seizures prior to death. However, using continuous IR video recording of B6 female *Gnao1* G184S mutant mice over \~900 mouse-days, we captured two deaths. Females were chosen for these studies due to the ability to group hour up to four mice for these long-term studies. In one instance, there was an apparent seizure with rearing and wild jumping (Fig. [1](#Fig1){ref-type="fig"}c and video supplement) observed during the night prior to the mouse being found dead in the cage. The second death showed no evident seizure.

Heterozygous *Gnao1*^+/G184S^ mice have EEG abnormalities {#Sec12}
---------------------------------------------------------

We also assessed video EEGs of B6 females (Fig. [1](#Fig1){ref-type="fig"}d, e). Mutant mice (age \~24 weeks) had a substantially elevated frequency of interictal epileptiform discharges (IEDs; 363, 296 and 460 IEDs/h for hets versus 2 and 24 IEDs/h for controls---unpaired *t* test *t* = 7.37 df = 2.2, *p* \< 0.02). The IEDs seemed to occur more frequently during electrographic sleep than during wakefulness. Frequently, they occurred in runs of 1--3 Hz, but over the 4--8 day monitoring period, none met criteria for frank electrographic seizures due to the short duration the discharges (\<10 s) nor were any overt seizures seen on video over this time period.

Heterozygous *Gnao1*^+/G184S^ mice are sensitized to PTZ kindling {#Sec13}
-----------------------------------------------------------------

To provide an independent and earlier assessment of the susceptibility to epileptogenesis in the mutant mice, we performed a PTZ kindling model in 8--12 week old mice (see "[Materials and Methods](#Sec2){ref-type="sec"}"). Female B6 *Gnao1*^+/G184S^ mutants were more sensitive to PTZ kindling than were controls (Fig. [2](#Fig2){ref-type="fig"}a Gehan--Breslow--Wilcoxon df(1) = 5.74, *p* \< 0.02). This was independent of gender (similar to spontaneous death) as mutant males also showed enhanced PTZ sensitization (Fig. [2](#Fig2){ref-type="fig"}b, Gehan--Breslow--Wilcoxon df(1) = 6.88, *p* \< 0.01).Fig. 2*Gnao1* ^+/G184S^ mice sensitize faster to repeated low-dose PTZ. The time to undergo sensitization to PTZ kindling (see Methods for definition) was recorded. **a** B6 female *Gnao1* ^+/G184S^ sensitize more rapidly than littermate controls (Gehan--Breslow--Wilcoxon df(1) = 5.74, *p* \< 0.05). **b** Similarly *Gnao* ^+/G184S^ males also sensitize more rapidly than littermate controls (Gehan--Breslow--Wilcoxon df(1) = 6.88, *p* \< 0.01). **c** B6 heterozygous knockout *Gnao1* ^+/−^ mutant females do not sensitize more rapidly than littermate controls (*p* \> 0.05)

To determine whether the cause of seizure susceptibility in our mice might be due to loss of function of *Gnao1* as suggested for humans in EIEE17 (Nakamura et al. [@CR27]), we evaluated *Gnao1* knockout mice. The homozygotes show early lethality (Valenzuela et al. [@CR30]) and we were unable to generate sufficient numbers to undertake studies. The heterozygous knockout (*Gnao1*^+/−^) mice showed no enhancement in sensitivity to PTZ kindling (Fig.  [2](#Fig2){ref-type="fig"}c). The wild-type mice did show earlier seizure onset than the WT controls for the *Gnao1* G184S mutants. This was unexpected. The most plausible explanation is that the two lines were developed from separate colonies and the backgrounds may be somewhat different despite both being C57Bl/6. The lack of increased kindling in the *Gnao1*^+/−^ mice combined with the normal level of expression of Gα~o~ in our *Gnao1* G184S mutants suggests that loss of function in our mutants does not explain our results (see "[Discussion](#Sec17){ref-type="sec"}").

Both spontaneous death and increased sensitivity to epileptogenesis are strain dependent {#Sec14}
----------------------------------------------------------------------------------------

Interestingly, *Gnao1* G184S heterozygous mutant mice on a 129 background (N6 129S1/SvImJ) live a relatively normal lifespan with 100 % surviving \> 1 year (Fig. [3](#Fig3){ref-type="fig"}a). This contrasts strongly with the \~50 % of mutants on the B6 background that die by 25--40 weeks (Fig. [3](#Fig3){ref-type="fig"}a). Paralleling the strain-dependent nature of the adult lethality, *Gnao1* G184S het mice on the 129 background also showed no difference in susceptibility to PTZ kindling compared to wild-type littermates (Fig. [3](#Fig3){ref-type="fig"}b). This suggests that one or more modifier loci that differ between B6 and 129 mice affects the penetrance of the lethality and seizure susceptibility phenotypes of the *Gnao1* G184S mutants. To determine whether the protective or susceptible alleles were dominant, we tested B6/129 F1 mice. No deaths were observed up to 47 weeks in F1 mice regardless of their gender (*n* = 16 per genotype Fig. [3](#Fig3){ref-type="fig"}c). Thus, 129 alleles appear to provide a dominant protective effect against the spontaneous death phenotype of the *Gnao1*^+/G184S^ mutation or, conversely, the C57BL/6J background effect is recessive. Similarly, *Gnao1* mutant mice on the B6/129 F1 background are protected against PTZ kindling (Fig. [3](#Fig3){ref-type="fig"}d, Gehan--Breslow--Wilcoxon df(1) = 7.9, *p* \< 0.01). Thus, a single copy of 129 alleles throughout the genome is sufficient for protection in kindling as well as for spontaneous lethality.Fig. 3Adult lethality and kindling sensitivity are suppressed on a 129 background. **a** While B6 (N7) Gnao1^+/G184S^ mutant mice die prematurely, mutants on a 129SvImJ strain background do not. **b** Similarly, the enhanced kindling sensitivity of Gnao1^+/G184S^ mutants is not seen on a 129 strain background. **c** The effect of the 129 background is dominant as 129/B6 F1 mice carrying the Gnao1 mutation do not show enhanced adult lethality. **d** Similarly, the increased kindling sensitivity of Gnao1^+/G184S^ mutants on the B6 background is partially ameliorated on the F1 background

Mapping modifier loci {#Sec15}
---------------------

Evaluating F2 offspring from intercrosses of B6/129 F1 mice carrying the *Gnao1* G184S mutant allele showed that only 4 out of 60 heterozygous mutant offspring died before one year of age. Genome-wide SNP analysis was done but the small number of mice with the lethal phenotype was insufficient to obtain statistically significant LOD scores (data not shown). Given that 25 % of the F2 mice should be homozygous for B6 alleles at any given locus, 15 mice should have died if there had been a single high-penetrance modifier region; this suggests that there may be more than one modifier.

As an alternative approach to define genetic loci underlying the strain differences, we did a preliminary genome scan on 18 progeny of a single N6 male *Gnao1* G184S mutation carrier. This analysis was based on the hypothesis that protective 129 alleles should be enriched in the long-lived group. Out of the 11 male and 7 female N7 B6 *Gnao1*^+/G184S^ mice from Fig. [3](#Fig3){ref-type="fig"}a, six were short-lived (i.e., died prior to the survival curve leveling off at \~25 weeks of age) and 12 were long-lived (i.e., alive past 25-week cutoff). The distribution of 129 (heterozygous) alleles across the genome was assessed by Illumina genotyping (see Supplemental Methods with confirmation markers defined in Table S1). The percent of short-lived and long-lived mice carrying 129 alleles at the indicated chromosomal location is shown in Fig. [4](#Fig4){ref-type="fig"}a, b. As expected, all mice retained 129 alleles on Chr 8 (i.e., those linked to the *Gnao1* locus). The only region that *preferentially* retained 129 alleles in the long-lived cohort was on Chr17 at a point after 39 Mb through the end of the chromosome (Fig. [4](#Fig4){ref-type="fig"}a, b). Details of other retained regions on Chr 5 and Chr16 are presented in Fig. S3a, b, respectively, and Table S2. This initial analysis was not sufficiently powered to statistically validate the modifier due to the corrections needed for multiple comparisons.Fig. 4Mapping a modifier of the strain-dependent lethality on Chromosome 17. A cohort of 18 *Gnao1* ^+/G184S^ mutant mice derived from a single N6 male founder was monitored for longevity. Whole genome SNP analysis was done comparing short-lived (*black*, dead by 25 weeks) versus long-lived (*red*, alive at 25 weeks). Regions of retained 129S alleles were assessed. **a** *Plots* show the percentage of the mutant mice carrying 129 alleles at a particular location in the genome (see **b** and Fig. S3 for specific marker locations). All mutant mice had 129 alleles linked to the *Gnao1* locus on Chr8. **b** Only one region, Chr 17, showed preferential retention of 129 alleles in the long-lived population. **c** Confirmation of the association of retained 129 alleles on Chr17 with longer survival was undertaken in an independent cohort of 44 mice. Those mice retaining 129 alleles on Chr 17 at both 47 and 62 Mb (but not at 41 and 70 Mb) showed increased survival (**c** Gehan--Breslow--Wilcoxon df(1) = 4.9, *p* \< 0.05)

To both confirm and reduce the size of the potential modifier region, we obtained recombinant mice that maintained 129 alleles at 47 and 62 Mb on Chr17 but were homozygous for B6 alleles at 41 and 70 Mb allowing us to reduce the size of the putative modifier region by half (see details of markers used in Table S1). In an independent experiment with 44 mice, we tested the ability of the (Chr17: 41--70 Mb) subregion to afford protection. This approach of identification followed by validation is supported by the previous literature (Williams and Haines [@CR32]). The presence of 129 alleles in the Chr17: 41--70 Mb subregion protected *Gnao1* G184S het mice from spontaneous death in the independent cohort (Fig. [4](#Fig4){ref-type="fig"}c Gehan--Breslow--Wilcoxon df(1) = 4.9, *p* \< 0.05). The other retained 129 regions (e.g., Chr5 and Chr16 in Fig. [4](#Fig4){ref-type="fig"}a) did not influence viability within this cohort (data not shown).

Chr 17 locus also modifies PTZ susceptibility {#Sec16}
---------------------------------------------

We next tested the hypothesis that the Chr17 spontaneous death modifier protected against enhanced PTZ susceptibility. In this case, experiments were restricted to females due to their enhanced rate of kindling. The presence of 129 alleles within the Chr 17: 41--70 Mb modifier region also protected B6 *Gnao1* mutant hets from kindling (Fig. [5](#Fig5){ref-type="fig"}a, Gehan--Breslow--Wilcoxon, df(1) = 4.28 *p* \< 0.05). To determine whether the effect of this Chr17: 41--70 Mb locus to protect against kindling depended on the presence of the *Gnao1* G184S mutant allele, we assessed its effect in *Gnao1* WT mice. As expected, mice without the *Gnao1* mutation showed markedly delayed kindling (half-max at injection 7, Fig. [5](#Fig5){ref-type="fig"}b vs. than 1 or 2 for the *Gnao1* mutants, Fig. [5](#Fig5){ref-type="fig"}a). There may be a small effect of 129 alleles in the Chr17: 41--70 Mb region on kindling of *Gnao1* WT mice but there was no statistically significant protection. The striking effect of this region in the presence of the *Gnao1* mutant prompted us to name this Chr17 locus *Mogs1* (modifier of G protein-induced PTZ susceptibility 1) in parallel with the *Moe1* and *Moe2* loci which have been previously described for protection against spontaneous seizures induced by sodium channel mutants (Bergren et al. [@CR1], [@CR2]).Fig. 5Chromosome 17 modifier region also affects sensitization to kindling of B6 *Gnao1* ^+/G184S^ mutants but not that of WT mice. **a** Female *Gnao1* mutant mice homozygous for B6 alleles at Chr17 (47--62 MB) sensitize to kindling faster than those heterozygous for 129 alleles at those loci. So the Chr17 region that protects against early lethality also delays sensitization to PTZ kindling (Gehan--Breslow--Wilcoxon df(1) = 7.9, *p* \< 0.01). **b** The modifier is dependent on G~o~ mutation status. **b** In a sample of similar size to that in 5A, the Chr 17 modifier region did not significantly alter sensitization to PTZ kindling in B6 *Gnao1* wt mice

Discussion {#Sec17}
==========

In this report, we show that mice heterozygous for the *Gnao1* G184S gain-of-function allele have partial perinatal lethality, spontaneous adult lethality, enhanced frequency of epileptiform discharges, and marked sensitization to PTZ kindling. These results are quite interesting in light of the recent finding by Nakamura et al. ([@CR27]) that four infants with epileptic encephalopathy (Ohtahara syndrome, EIEE17) have de novo, non-synonymous polymorphisms in GNAO1. Our results with the gain-of-function allele contrast with those for heterozygous *Gnao1*± knockout mice which do not have increased kindling sensitivity and have not been reported to have seizures, though homozygous knockouts do (Valenzuela et al. [@CR30]).

It is of great interest to understand whether the mechanisms of the seizure phenotype in humans with GNAO1 mutations and in our mice (*Gnao1*^+/G184S^) are similar. Our mutant allele is well documented as having enhanced function. In vitro studies with opioid receptors to inhibit both cAMP levels (Clark et al. [@CR7]) and N-type Ca^++^ channels (Ikeda and Jeong [@CR16]) show profound increases in Gα~o~ function with the G184S mutation. In brain slices, the mutation also enhances presynaptic inhibition by adenosine (Chen and Lambert [@CR5]) and epinephrine (Goldenstein et al. [@CR13]). In vivo opioid signaling is also enhanced in *Gnao1*^+/G184S^ mutant mice and reduced in *Gnao1*^+/−^ mice (Lamberts et al. [@CR18]). The human GNAO1 mutants alleles analyzed in vitro by Nakamura et al. ([@CR27]) were interpreted as providing evidence for loss of function. It is somewhat surprising to see haploinsufficiency in this context since heterozygous *Gnao1* knockout mice do not show seizures. Indeed, at least two of the four human mutants (N174G and T191-F197del) produced spontaneously lower Ca^++^ channel currents which might instead represent a gain of function. Interestingly, loss-of-function mutations in P/Q-type Ca^++^ channels (Cav2.1, CACNA1A) cause absence of seizures in humans; mouse knockouts produce seizures and early lethality (Khosravani and Zamponi [@CR17]). Since Gα~o~ signaling can suppress both N- and P/Q-type calcium channel activity, a gain-of-function allele in GNAO1 is potentially a pro-seizure mechanism.

While brain morphology changes are seen in 3 of the 4 cases of EIEE17, we did not see any gross alterations in brain morphology in our *Gnao1* mutant mice nor were such changes seen in *Gnao1* homozygous knockouts (Valenzuela et al. [@CR30]). It is not clear whether the effect of the *Gnao1* G184S mutation is through alterations in brain development or simply through enhanced function. Increased *Gnao1* signaling to N- and P/Q-type Ca^++^ channels would be expected to suppress neurotransmitter release which might be expected to have antiepileptic actions. However, both gain and loss of sodium channel activity can lead to seizures (Meisler and Kearney [@CR24]), so a similar phenomenon may be at play here. If enhanced Gα~o~-mediated presynaptic inhibition occurred in inhibitory (GABAergic) neurons, as has been proposed for the epileptogenic Nav1.1 LOF mutants (Yu et al. [@CR33]), one could see hyper-excitability due to suppressed inhibitory tone. This is consistent with our prior observation of reduced in vitro excitability in hippocampal slices from mice carrying our mutation (Goldenstein et al. [@CR13]). In that model, the ability of epinephrine to suppress hippocampal epileptiform discharges was enhanced in the Gα~o~^+/G184S^ mutants. Since inhibitory signaling was abrogated in that model with picrotoxin, the pro-seizure behavior that we see here would have been missed if the mechanism is suppression of inhibitory signaling. Further study will be necessary to distinguish between structural and functional mechanisms.

The present study also suggests a role for G~o~ signaling in sudden unexplained death in epilepsy (SUDEP). One proposed mechanism of SUDEP is post-ictal bradycardia or hypoventilation (Surges and Sander 2012). In addition to the increase in interictal epileptiform discharges and spontaneous death reported here, the Gα~o~ G184S mutation also enhances bradycardia to muscarinic and adenosine signaling (Fu et al. [@CR11]). Increased bradycardia or effects on brainstem control of ventilation could contribute to the lethality that we observe. Clearly, further study of this is needed.

In addition to the effect of the *Gnao1* G184S mutation, we have identified a second locus that ameliorates the phenotype in our *Gnao1* mutant mice. Both spontaneous deaths and enhanced kindling sensitization were substantially mitigated in the presence of 129 alleles derived from a 29 Mb modifier region on Chr 17, which we term modifier of G protein-induced seizures 1 (*Mogs1*). It is of interest that the protective modifier alleles on Chr17 come from the 129 strain which is more sensitive to PTZ kindling compared to C57Bl/6J. This, however, is relatively common in epilepsy models (Bergren et al. [@CR2]). The modifier region appears to have its effect on PTZ susceptibility primarily in *Gnao1* mutant mice. Also, *Mogs1* seems not to influence effects of acute PTZ administration as it was not found in a genomic analysis of acute PTZ-induced seizures (high dose---80 mg/kg) in B6 vs DBA mice (Ferraro et al. [@CR10]). These observations suggest that this modifier region (*Mogs1*) may have a unique interaction with G~o~ function or perhaps in PTZ kindling-type remodeling mechanisms but not in acute seizures. Defining the specific genes and alleles that underlie its effect will be important.

The *Mogs1* region (Chr17: 41--70 Mb) includes the coding sequences of \~130 known proteins. One that was an obvious candidate was Rab5a, the gene product of which has been proposed as a novel G~o~ effector in Drosophila (Purvanov et al. 2010). Loss of an effector molecule could easily suppress a gain-of-function mutation in G~o~. There are no non-synonymous coding SNPs in *Rab5a* between 129 and B6 strains. Despite several SNPs in the 5′ and 3′ UTR, there were no changes in mRNA expression as detected by quantitative real-time PCR (data not shown). Thus, *Rab5a* does not appear to be the modifier gene. To develop a list of other possible candidates, we looked for non-synonymous SNPs or splice site variants identified in the Sanger informatics website. Three proteins have altered stop codons. Two genes, *9130008F23Rik* K55\* and *Trem2* 149\*, have premature stops, while *Yipf3* lost a stop codon, \*202 W. *Polh* has a variant in a splice site, while *Ttbk1,Tbc1d5*, and *Lrfn2* have in-frame dels in the 129S sequence. For non-synonymous SNPs, the predicted effect on protein function was assessed using Provean (Choi et al. 2012). Seven genes *Pgk2*, *Gpr115*, *Gm5093*, *BC048355*, *Lrfn2*, *Kcnh8,* and *Vmn2r118* were predicted to have non-synonymous SNPs disruptive of protein function in the 129S strain. *Gpr115* is an obvious high-priority candidate. In addition to documented SNPs between 129S and B6 strains, we also generated a candidate list of 20 genes based on known CNS function or roles in GPCR signaling. These lists represent a starting point for future candidate analysis in conjunction with higher resolution experimental mapping of *Mogs1*. Whole exome and targeted exome sequencing is currently underway.

In summary, we demonstrate that a *Gnao1* gain-of-function mutation causes a sudden death phenotype with associated seizures, increases sensitivity to PTZ kindling, and enhanced frequency of spontaneous epileptiform discharges in C57BL/6J mice. This provides a novel experimental model with potential relevance to a subset of Ohtahara syndrome (EIEE17) and possibly SUDEP in humans. Further study of the mechanism of this mouse model, as well as identification of the genes involved in the modifier locus on Chr17, should provide insights into the complex genetic basis of human epilepsy.
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